Vermont Mom: Did You Know? The HPV Vaccine.

Have you been receiving reminders about vaccination requirements and recommendations for middle school? Parents of 6th graders in Vermont public schools report receiving recent emails from their school nurses reminding them to vaccinate their children for 7th grade. After receiving an e-mail informing her that the HPV vaccine was recommended for her 6th grade daughter to “prevent cancers,”  this is what one Mom had to say {download .pdf copy}.

View all VAERS reports from Vermont here
The HPV vaccine was fast tracked by the FDA in 2006. This is a temporary process, designed to allow drugs to hit the market before they demonstrate any real benefit. This means that the pharmaceutical companies did not have to prove that the HPV vaccine is capable of preventing cancer prior to FDA approval.  To date, there are still no studies proving that the HPV vaccine is capable of cancer prevention. It will be decades before those data are available. Claims of cancer prevention by the HPV vaccine at this time are based on assumptions.

It is important to understand that HPV infection does not equal cancer.  Over 90% of HPV infections are self-limiting, meaning that your body resolves them completely without any intervention. Of the 10% that do not resolve, only a very small fraction progress on to the cervical cancer stage and this progression is extremely slow, taking 15-30 years. If protection does not last at least 15-30 years, the time frame in which cervical cancer would develop, then the vaccine offers only risk with no benefit. At this time, the duration of protection is unknown according to the CDC.

Another consideration is that fact that there are over a dozen HPV strains associated with cancer and the vaccine does not cover all of them. When you vaccinate against the most common strains, others that are currently less prevalent can step in and take their place. There is research suggesting that this is already happening in vaccinated populations and it is a real possibility that strain replacement could negate the effects of the vaccine or even increase cancer rates.

HPV vaccine safety studies for FDA approval followed 1,200 girls for less than 2 years and did not use a true placebo group, which is the foundation of solid scientific research. This means that long-term safety data is based on post-market surveillance, a fancy way of saying that your child will be a part of the experiment. Merck’s HPV vaccine insert states that 2.3% of study participants reported serious adverse reactions. As of January 14, 2018 there were 56,168 reports adverse reactions to the HPV vaccine, including 15,145 emergency room visits and 412 deaths submitted to the federal government’s Vaccine Adverse Events Registry. There is also concerning evidence that the HPV vaccine may increase your risk of cancer if you have previously been exposed to vaccine strains of HPV, which they do not test for before administering the vaccine. The risks are real and the benefits (cancer prevention) are currently hypothetical.

FDA guidelines permit fast tracking when there is a significant benefit from the new therapy beyond anything else currently available, or if no therapy currently exists.  According to mathematical modeling studies, the pap test remains superior to the HPV vaccine as a cervical cancer prevention strategy. It seems that the HPV vaccine was unnecessarily given fast track approval. Cervical cancer rates in Vermont are 5.7/100,000.  The rate of serious adverse events reported after vaccination was 2,300/100,000 according to Merck. The pap test carries virtually zero risk. Vaccination is a medical intervention recommended for healthy individuals, as such, the benefits must clearly outweigh the risks.

Independent research shows that the antibodies made to the HPV vaccine can attack human tissues – the definition of autoimmune disease. Research has shown that the “number of viral matches and their locations make the occurrence of side autoimmune cross-reactions in the human host following HPV16-based vaccination almost unavoidable.” Why is this not front page news? Autoimmune diseases – think lupus, multiple sclerosis, allergies, asthma, eczema, alopecia…may not show up for months, years, or decades making it virtually impossible to trace back to vaccine exposure. Both parents and health care professionals should demand that all vaccine antigens are tested for cross-reactivity with the human proteome before FDA approval.

I understand that your job is to provide CDC-based information, however given the complexity of the issue and the cozy relationship between the CDC and Pharma, I think it important to be aware of the larger body of research regarding this vaccine.  I have included references below. I have also attached a video of pathologist Dr. Sing Lee addressing the issue of HPV vaccine contamination with HPV DNA fragments. Typically, foreign DNA fragments would be readily cleared from the body, but the HPV DNA fragments found in the vaccine are tightly bound to the aluminum adjuvant.  This means that the body can not clear the foreign HPV DNA. Christopher Exley and his team at Keele University have demonstrated that macrophages engulf aluminum adjuvants at the vaccine injection site and transport it throughout the body depositing it in tissues, including the brain. This is problematic considering the reason aluminum is used in vaccines is to incite an inflammatory response.  We are now left with the real possibility of HPV DNA fragments attached to the aluminum adjuvant being transported into the brain causing chronic inflammation that may manifest as any manner of neurological conditions depending on the severity, location and timing.

– Naomi Malik


Kanduc D. Potential cross-reactivity between HPV16 L1 protein and sudden death-associated antigens. J Exp Ther Oncol. 2011;9(2):159-65. PubMed ID: 21699023.

Kanduc D. Quantifying the possible cross-reactivity risk of an HPV16 vaccine. J Exp Ther Oncol. 2009;8(1):65-76. PubMed ID: 19827272.

Tomljenovic L, Spinosa JP, Shaw CA. Human papillomavirus (HPV) vaccines as an option for preventing cervical malignancies: (how) effective and safe? Curr Pharm Des. 2013;19(8):1466-87. Review. PubMed ID: 23016780.

Guo, F., Hirth, J. M., & Berenson, A. B. (2015). Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20–26 years). Human Vaccines & Immunotherapeutics, 11(10), 2337–2344. PMID: 26376014

Harper DM, Vierthaler SL, Santee JA. Review of Gardasil. J Vaccines Vaccin. 2010 Nov 23;1(107). PubMed ID: 23805398




Mold M, Umar D,  King A,  Exley C. Aluminium in brain tissue in autism. J Trace Elements in Med and Biol. 2018
Volume 46, Pages 76-82. Accessed 4/4/2018 at